HOME >> BIOLOGY >> NEWS
Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer

PHILADELPHIA A therapeutic cancer vaccine has shown effectiveness when given alongside chemotherapy to patients with metastatic colorectal cancer in a phase II trial, according to researchers at Oxford BioMedica (UK) Ltd. The study found that six of the 17 metastatic colorectal cancer patients in the study showed tumor shrinkage, classified as complete or partial responses following independent expert review.

The study, reported in the August 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, was designed to demonstrate the safety and immunogenicity of the vaccine, called modified vaccinia Ankara-encoding 5T4 (TroVax), when used alongside standard chemotherapy. The research was funded by Oxford BioMedica which is developing the vaccine in partnership with Sanofi-Aventis.

Unlike preventative vaccines, such as the human papillomavirus vaccine to prevent cervical cancer, TroVax is a therapeutic vaccine, designed to stimulate the immune systems of patients who already have cancer. The vaccine consists of an attenuated (non-disease causing) version of the vaccinia virus modified to deliver the gene for 5T4, a protein found in many tumors.

The idea is that the modified virus enters cells, produces the tumor protein and stimulates the immune system, said lead study author Richard Harrop, Ph.D., vice president of clinical immunology at Oxford BioMedica. To give a vaccine alongside chemotherapy might seem counterintuitive, since chemotherapy can weaken the immune system, but our study shows that TroVax could be complementary to standard chemotherapy, enhancing the immune response to tumors.

The target of this immuno-therapy approach is a tumor antigen called 5T4, a protein embedded within the membrane of cancer cells. The protein is rarely found in normal tissues, but is produced at high levels by a wide range of human cancers, including colorectal, renal, gastric and ovarian. The
'"/>

Contact: Greg Lester
lester@aacr.org
267-646-0554
American Association for Cancer Research
1-Aug-2007


Page: 1 2 3

Related biology news :

1. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
2. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
3. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
4. Phase III trials of cellulose sulfate microbicide for HIV prevention closed
5. Phylonix awarded National Science Foundation Phase II SBIR for zebrafish screening
6. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants
7. Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis
8. REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement
9. New Phase 3 data show potential benefits of Aranesp dosed every three weeks for CIA
10. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
11. Centocor & Schering-Plough next generation biologic promising in Phase 2 rheumatoid arthritis trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) today ... of up to $250 million of the company,s common ... remain open through December 31, 2017. Purchases may be ... in privately negotiated transactions from time to time as ...
(Date:4/27/2017)... ... April 27, 2017 , ... Arrowhead Publishers is pleased to ... coming to San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, ... advances in the treatment of various types of pain. There are also extended ...
(Date:4/27/2017)... ... April 27, 2017 , ... The ... Communication Award goes to Jayson Lusk, a consummate communicator who promotes agricultural science ... advocate for science, as he explains how innovation and growth in agriculture are ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ... I clinical trials comes to Tampa, San Francisco and Boston in 2017. ... FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix ...
Breaking Biology Technology:
Cached News: